Wellgistics Health, Inc. (NASDAQ:WGRX) announced that it has selected five blockchain platforms—Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum/Besu, and Corda (R3)—to build its PharmacyChain™ smart‑contract‑enabled drug‑tracking system. The decision follows the company’s goal of creating a secure, transparent supply‑chain solution that supports the U.S. Drug Supply Chain Security Act serialization mandate and positions PharmacyChain as a competitive alternative to traditional wholesalers.
The selection of multiple platforms reflects Wellgistics’ strategy to leverage the strengths of each network: Hyperledger Fabric for enterprise permissioned chains, Ethereum/Polygon for broad developer support, VeChain for supply‑chain focus, Quorum/Besu for privacy and scalability, and Corda for regulated financial transactions. By integrating these technologies, the company aims to accelerate the beta launch of PharmacyChain in the first half of 2026 and expand its addressable market from the current $634 billion U.S. pharmaceutical distribution market to an estimated $883 billion by 2030.
The announcement signals a significant shift in Wellgistics’ technology roadmap, as the company moves beyond its EinsteinRx AI platform toward a full blockchain‑enabled ecosystem. “Now that we have identified what we believe are the best technologies currently available upon which to build PharmacyChain, we are beginning the development work needed to make it operational initially within our own pharmacy by the end of next quarter,” said Prashant Patel, RPh, President & Interim‑CEO. “We are making the integration of smart contracts a central pillar for our growth strategy going forward, allowing us to differentiate ourselves in the traditional pharmaceutical distribution and compound pharmacy spaces.”
Wellgistics faces significant financial challenges, including liquidity constraints and a low stock price. The company has recently secured convertible‑note funding to shore up near‑term liquidity, but investors will watch how capital is allocated to develop and commercialize PharmacyChain, given the need to demonstrate early adoption to secure additional funding.
The move underscores the firm’s commitment to meeting industry serialization requirements and differentiating itself from the dominant distributors—McKesson, Cencora, and Cardinal Health—by offering independent pharmacies a transparent, cost‑effective tracking solution.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.